Sinovac Biotech (Sinovac Biotech) Total Current Liabilities : $1,189.6 Mil (As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Sinovac Biotech's total current liabilities for the quarter that ended in Jun. 2023 was $1,189.6

Sinovac Biotech Total Current Liabilities Historical Data

The historical data trend for Sinovac Biotech's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Total Current Liabilities Chart

Sinovac Biotech Annual Data

Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22

Total Current Liabilities

Get a 7-Day Free Trial 58.21 87.20 679.61 2,412.85 1,091.64

Sinovac Biotech Semi-Annual Data

Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23

Total Current Liabilities Get a 7-Day Free Trial 3,307.74 2,412.85 564.86 1,091.64 1,189.63

Sinovac Biotech Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Sinovac Biotech's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 1047.916 + 10.644

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 33.075

= 1,091.6

Sinovac Biotech's Total Current Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 959.077 + 211.267

+ Other Current Liabilities + Current Deferred Liabilities

= -2.2737367544323E-13 + 19.285

= 1,189.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Sinovac Biotech Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Sinovac Biotech's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (Sinovac Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Total Current Liabilities

Comparable Companies

INBX HLVX KOD ALT INO GLUE VXRT PTGX IMGO MRSN OCSE:NOVO B ASX:CSL VRTX REGN MRNA XKRX:207940 HKSE:02269 SGEN BNTX SZSE:300122

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030

Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000

Yin Weidong director, 10 percent owner, officer: President and CEO

Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC Reports Unaudited First Half of 2023 Financial Results
By Business Wire • 08-15-2023

SINOVAC Varicella Vaccine Prequalified by WHO
By Business Wire Business Wire • 11-04-2022

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil
By Business Wire Business Wire • 07-14-2022

SINOVAC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sinovac Biotech Ltd. and Encourages Investors to Contact the Firm
By Business Wire Business Wire • 08-19-2022

Sinovac Announces Change of Legal Representative of Sinovac Beijing
By Business Wire • 08-28-2023

ROSEN, A LEADING LAW FIRM, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVA
By PRNewswire PRNewswire • 08-30-2022

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers � SVA
By PurpleRose PurpleRose • 08-20-2022

EQUITY ALERT: Rosen Law Firm Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers � SVA
By Business Wire Business Wire • 08-17-2022

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile
By Business Wire Business Wire • 07-19-2022

SINOVAC BIOTECH LTD. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts
By PRNewswire PRNewswire • 08-30-2022

Sinovac Biotech Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Current Liabilities	Get a 7-Day Free Trial															3,307.74	2,412.85	564.86	1,091.64	1,189.63

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	1047.916	+	10.644
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0	+	33.075
	=	1,091.6

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6